FDA Public Meeting On Rx Risk, Benefit Communication Slated For December
Executive Summary
FDA will hold a public hearing on ways to better communicate information about drug risks and benefits, FDA Drug Safety Oversight Board Executive Director Susan Cummins said at the PDA/FDA Joint Regulatory Conference in Washington, D.C. on Sept. 13
You may also be interested in...
FDA Drug Risk Communication Should Include Drug Benefit Info, PhRMA Says
FDA risk communication materials should include information about a drug's benefits to avoid scaring patients away from their medications, the Pharmaceutical Research & Manufacturers of America said
FDA Drug Risk Communication Should Include Drug Benefit Info, PhRMA Says
FDA risk communication materials should include information about a drug's benefits to avoid scaring patients away from their medications, the Pharmaceutical Research & Manufacturers of America said
FDA’s Drug Safety Oversight Board Adds Staff To Manage Operations
FDA is adding three new staffers dedicated to working full time on the operations and communications of the Drug Safety Oversight Board